Human element important for decentralized trial advancement

Approximately two years after the pandemic morphed the decentralized clinical trial (DCT) from an emerging format to a necessity, the industry has learned numerous lessons about how to operate a DCT, as well as the benefit of incorporating DCT technology into an operation. However, as a trio of industry veterans shared during the recent Decentralized Trial Technology webinar​, there are still lessons yet to learn in order to make the most of DCTs.

On July 20, Outsourcing-Pharma hosted leaders from CVS Health, the Association of Clinical Research Professionals (ACRP), and the University of Chicago Medicine to discuss issues impacting the field. The representatives discussed common misconceptions about DCTs, patient considerations, novel tools and technologies, and more.

Mohammed Ali, an ACRP board member, shared that ACRP’s mission focuses on increasing the quality of clinical research overall through the direct impact of professionals that manage clinical studies, “to deliver the highest outcomes for patients worldwide​.”

Ali pointed out that the DCT format emerged, long before COVID-19 arrived on the scene, as a way to help manage a range of challenges, from cost and resource constraints to patient burden considerations.

“A decentralized clinical trial looks to deliver research in a remote capacity to increase access and democratize research for the majority of its participants as well as sponsors​,” Ali shared, adding that other concerns associated with traditional-format trials (such as drug stability and patient safety) do not go away with the change in location.

Source link

Leave A Reply

Your email address will not be published.